November 29, 2016 - By olga
A document filed with the Security Exchange Commission on 29/11/2016 revealed that John Pappajohn, the director of Cancer Genetics Inc, ‘s company acquired 100,000 shares. With average share price of $1.5, the trade’s value is $145,280 US Dollars. This is not his first insider trade, in the last 30 days, he obtained another 31,100 shares worth $46,050 USD. At the moment, John Pappajohn has ownership of 2.42 million shares or 12.42% of the company’s market capitalization (total value of the shares outstanding).
Out of 3 analysts covering Cancer Genetics (NASDAQ:CGIX), 2 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 67% are positive. $8 is the highest target while $6 is the lowest. The $7 average target is 337.50% above today’s ($1.6) stock price. Cancer Genetics has been the topic of 3 analyst reports since March 11, 2016 according to StockzIntelligence Inc. Rodman & Renshaw initiated Cancer Genetics Inc (NASDAQ:CGIX) rating on Monday, September 26. Rodman & Renshaw has “Buy” rating and $6 price target. The rating was maintained by Aegis Capital with “Buy” on Tuesday, March 15. Janney Capital downgraded the stock to “Neutral” rating in Friday, March 11 report.
Insitutional Activity: The institutional sentiment decreased to 0.73 in 2016 Q2. Its down 0.77, from 1.5 in 2016Q1. The ratio is negative, as 6 funds sold all Cancer Genetics Inc shares owned while 4 reduced positions. 6 funds bought stakes while 9 increased positions. They now own 1.58 million shares or 24.74% more from 1.27 million shares in 2016Q1.
Pnc Financial Ser Inc accumulated 0% or 21,000 shares. Perkins Management Inc holds 1.33% of its portfolio in Cancer Genetics Inc (NASDAQ:CGIX) for 581,200 shares. Morgan Stanley reported 20,542 shares or 0% of all its holdings. Jpmorgan Chase & last reported 0% of its portfolio in the stock. Globeflex Capital Lp has 0% invested in the company for 317 shares. Advisory Ntwk Limited Liability holds 0% of its portfolio in Cancer Genetics Inc (NASDAQ:CGIX) for 500 shares. Sabby Mgmt Limited Com has invested 0.02% of its portfolio in Cancer Genetics Inc (NASDAQ:CGIX). National Bank & Trust Of America De owns 569 shares or 0% of their US portfolio. Royal Bancorp Of Canada, a Ontario – Canada-based fund reported 97 shares. Blackrock Invest Limited Liability Company, a New Jersey-based fund reported 2,086 shares. Blackrock Institutional Trust Na accumulated 12,424 shares or 0% of the stock. Citadel Advsr Lc, a Illinois-based fund reported 14,979 shares. Tocqueville Asset Management Ltd Partnership, a New York-based fund reported 23,800 shares. Sterneck Capital Mgmt Limited Company accumulated 0.02% or 14,750 shares. Goldman Sachs Gp has invested 0% of its portfolio in Cancer Genetics Inc (NASDAQ:CGIX).
Insider Transactions: Since August 12, 2016, the stock had 4 buys, and 1 sale for $470,098 net activity. 5,000 shares were bought by Harris Geoffrey E., worth $7,750. On Wednesday, November 16 Sitar Edward J sold $5,193 worth of the stock or 3,333 shares. PAPPAJOHN JOHN had bought 147,500 shares worth $318,288.
The stock increased 3.23% or $0.05 on November 29, hitting $1.6. About 122,016 shares traded hands. Cancer Genetics Inc (NASDAQ:CGIX) has declined 44.44% since April 26, 2016 and is downtrending. It has underperformed by 49.70% the S&P500.
Cancer Genetics, Inc. is engaged in the field of personalized medicine, enabling precision medicine in the field of oncology through its diagnostic services and products, and molecular markers. The company has a market cap of $29.28 million. The Firm develops, commercializes and provides molecular- and biomarker tests and services that enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor and inform cancer treatment, and enable biopharmaceutical companies engaged in oncology trials to select candidate populations and manage adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics. It currently has negative earnings. It has a range of disease-focused oncology testing portfolio.
According to Zacks Investment Research, “Cancer Genetics, Inc. operates as a diagnostics company focused on developing and commercializing proprietary genomic tests and services to improve the diagnosis, prognosis and response to treatment of cancer. The company’s tests target cancers, including hematological, urogenital, and HPV-associated cancers. It also offers non-proprietary oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals as well as biopharma and biotech. Cancer Genetics, Inc. is headquartered in Rutherford, New Jersey.”
Analysts await Cancer Genetics Inc (NASDAQ:CGIX) to report earnings on March, 9. They expect $-0.23 earnings per share, up 52.08% or $0.25 from last year’s $-0.48 per share. After $-0.23 actual earnings per share reported by Cancer Genetics Inc for the previous quarter, Wall Street now forecasts 0.00% EPS growth.
More notable recent Cancer Genetics Inc (NASDAQ:CGIX) news were published by: Globenewswire.com which released: “Cancer Genetics, Inc. to Present at the Dawson James Securities Growth Stock ..” on October 14, 2016, also Globenewswire.com with their article: “Cancer Genetics, Inc. Ranked Among Fastest Growing Companies For Third ..” published on November 16, 2016, Globenewswire.com published: “Cancer Genetics, Inc. Launches Focus::Renalâ„¢, a Unique, Comprehensive and ..” on November 02, 2016. More interesting news about Cancer Genetics Inc (NASDAQ:CGIX) were released by: Globenewswire.com and their article: “Cancer Genetics Inc. Selected by H3 Biomedicine Inc., to Provide Biomarker ..” published on July 18, 2016 as well as Seekingalpha.com‘s news article titled: “Cancer Genetics: ‘Warrant,’ You Are Under Arrest” with publication date: July 15, 2016.
Cancer Genetics, Inc., incorporated on April 8, 1999, is engaged in the field of personalized medicine, enabling precision medicine in the field of oncology through its diagnostic services and products and molecular markers. The Firm develops, commercializes and provides molecular- and biomarker tests and services that enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor and inform cancer treatment, and enable biopharmaceutical companies engaged in oncology trials to select candidate populations and manage adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics. It has a range of disease-focused oncology testing portfolio. The Company’s molecular- and biomarker diagnostic services are for three main sectors: cancer centers and hospitals, biotechnology and biopharmaceutical companies, and the research community. The Company’s services include clinical services, biopharma services and discovery services.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.